Press releases

Non Regulatory

December 29, 2020

Oasmia Secures Valuable IP Rights in Australia and Brazil

Regulatory

December 28, 2020

Oasmia’s partner Elevar Therapeutics signs licensing agreement with Inceptua Group for the commercialization of Apealea® (paclitaxel micellar) in Europe

Regulatory

December 9, 2020

Interim report¹ for the period May 1, 2020 – October 31, 2020

Regulatory

December 3, 2020

Oasmia’s Partner Elevar Provides an Update on Apealea Development Plans in Ovarian Cancer

Non Regulatory

November 30, 2020

Invitation to presentation of Oasmia’s Q2 report on December 9

Non Regulatory

November 27, 2020

Oasmia appoints Robert Maiorana as acting CFO

Regulatory

November 20, 2020

Nomination Committee appointed for the 2021 Annual General Meeting in Oasmia

Non Regulatory

November 3, 2020

Oasmia to present at Investival Showcase November 11-16

Non Regulatory

October 26, 2020

Oasmia Secures Important IP Rights

Non Regulatory

October 20, 2020

Oasmia to present at Bio Europe Digital on October 26-29

Regulatory

October 14, 2020

The Disciplinary Committee of Nasdaq Stockholm orders Oasmia to pay a fine

Regulatory

October 5, 2020

Oasmia’s partner Elevar Therapeutics signs agreement with Taiba Middle East FZ LLC for commercialization of Apealea® in the Middle East and North Africa Region

Regulatory

September 25, 2020

Oasmia Brings an Action against the Former Board of Directors

Non Regulatory

September 24, 2020

Oasmia to present at Penser’s cancer research day October 7

Non Regulatory

September 23, 2020

Oasmia to present at Penser’s Bolagsdag September 24

Non Regulatory

September 16, 2020

Oasmia to present at Sachs Associates’ 20th Annual Biotech in Europe Forum

Regulatory

September 9, 2020

Report from Annual General Meeting of Oasmia Pharmaceutical AB

Regulatory

September 9, 2020

Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – July 31, 2020

Regulatory

September 8, 2020

Oasmia Pharmaceutical Appoints Fredrik Järrsten as Chief Financial Officer

Regulatory

September 2, 2020

Oasmia’s Nomination Committee revises its proposal for the AGM regarding Board of Directors

Non Regulatory

September 1, 2020

Oasmia to present at Aktiedagen Digitalt on September 15

Non Regulatory

September 1, 2020

Invitation to presentation of Oasmia’s Q1 report 2020/2021 on September 9, 2020

Regulatory

August 31, 2020

CFO of Oasmia, Michael af Winklerfelt has resigned

Non Regulatory

August 31, 2020

Oasmia to present at Aktiedagen Digital on September 8

Regulatory

August 19, 2020

Oasmia publishes its annual report

Regulatory

August 10, 2020

Notice of Annual General Meeting in Oasmia Pharmaceutical AB

Non Regulatory

August 10, 2020

Oasmia Pharmaceutical Appoints Peter Selin as Chief Business Officer

Regulatory

July 27, 2020

Oasmia’s partner Elevar Therapeutics and Tanner Pharma Announce Global Named Patient Program to Provide Access to Apealea®

Regulatory

June 18, 2020

Oasmia Pharmaceutical AB (publ). Year-end report for the financial year May 1, 2019 – April 30, 2020

Non Regulatory

June 9, 2020

Invitation to presentation of Oasmia’s Year End Report 2019/2020 on June 18, 2020

Non Regulatory

June 8, 2020

Oasmia Pharmaceutical AB Signs Phase 1b Trial Agreement with SAKK, The Swiss Group for Clinical Cancer Research for Evaluation of Docetaxel Micellar

Non Regulatory

June 5, 2020

Oasmia to present at Aktiespararna’s Småbolagsdagar on 10 June

Non Regulatory

June 2, 2020

Oasmia to present at Avanza Börsdag on 3 June 2020

Non Regulatory

June 1, 2020

Oasmia Pharmaceutical has entered into a settlement agreement in US class action

Regulatory

May 14, 2020

Oasmia Pharmaceutical supplements bulletin from Extraordinary General Meeting

Regulatory

May 14, 2020

Oasmia Pharmaceutical Announces Results of Extraordinary General Meeting and Board Changes

Non Regulatory

May 14, 2020

Oasmia Pharmaceutical announces poster presentation at American Society of Clinical Oncology 2020 annual meeting

Regulatory

May 13, 2020

Oasmia announces outcome of strategic review to deliver long-term, profitable growth as a specialty pharma company

Non Regulatory

April 21, 2020

Oasmia receives upfront payment of 20 MUSD from Elevar

Regulatory

April 17, 2020

Notice of extraordinary general meeting in Oasmia Pharmaceutical AB

Regulatory

April 17, 2020

Oasmia Nomination Committee suggest changes in the Board of Directors

Regulatory

March 27, 2020

Oasmia Pharmaceutical AB (publ) Interim report for the period May 1, 2019 – January 31, 2020

Regulatory

March 25, 2020

Oasmia and Elevar sign a global strategic partnership for the commercialization of Apealea® with an upfront payment of USD 20 million, milestone payments with a potential of up to USD 678 million and double digit royalties.

Non Regulatory

March 23, 2020

Oasmia presents Q3 report through audiocast on March 27

Non Regulatory

March 9, 2020

Nomination committee in Oasmia for the 2020 AGM

Regulatory

February 14, 2020

Oasmia appoints new CEO

Non Regulatory

January 30, 2020

Oasmia launches the ovarian cancer treatment drug Apealea® in Sweden, Denmark and Finland

Non Regulatory

January 9, 2020

Oasmia to present at Biotech Showcase in San Francisco